Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.

Area of Science:

• Hematology
• Transplantation Immunology

Background:

• Hematopoietic stem cell transplant (HSCT) is a cornerstone therapy for hematological malignancies.
• Stem cells for HSCT can be sourced from bone marrow (BM), peripheral blood (PBSC), or cord blood (CB), each with distinct profiles.

Purpose of the Study:

• To compare the efficacy and safety of different stem cell sources for HSCT in hematological malignancies.
• To inform clinical decision-making regarding optimal stem cell source selection.

Main Methods:

• Review of randomized controlled trials (RCTs) comparing BM and PBSC for HSCT.
• Analysis of outcomes including survival, relapse, disease-free survival, graft failure, and graft-versus-host disease (GVHD).

Main Results:

• In matched sibling transplants, PBSC and BM show comparable survival, but PBSC may lower relapse risk at the cost of increased GVHD.
• In unrelated donor transplants, PBSC and BM yield similar survival, with PBSC associated with lower graft failure but higher chronic GVHD.
• Limited high-level evidence exists for cord blood (CB) compared to BM or PBSC.

Conclusions:

• The choice of stem cell source (BM, PBSC, CB) involves balancing risks and benefits, influenced by conditioning regimens, GVHD prophylaxis, and graft manipulation.
• Emerging techniques like double CB and haploidentical transplants add complexity to source selection.
• Individualized patient and donor counseling is crucial for informed decision-making in HSCT.